InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
| Product | Citation | Year | Journal | Authors | Page |
|---|---|---|---|---|---|
| Pam2CSK4 | Intra-pulpal connective tissue formation and the advanced carious lesion: Is ... | 2022 | Int Endod J. | Demant S. et al. | DOI: 10.1111/iej.13821 |
| Blasticidin | SMYD3 promotes aerobic glycolysis in diffuse large B-cell lymphoma via H3K4me... | 2022 | Cell Death Dis. | Tian T. et al. | DOI: 10.1038/s41419-022-05208-7 |
| Puromycin | SMYD3 promotes aerobic glycolysis in diffuse large B-cell lymphoma via H3K4me... | 2022 | Cell Death Dis. | Tian T. et al. | DOI: 10.1038/s41419-022-05208-7 |
| Fc-mDectin-1a | A Novel C-Type Lectin Receptor-Targeted α-Synuclein-Based Parkinson Vaccine I... | 2022 | Vaccines (Basel) | Schmidhuber S. et al. | DOI: 10.3390/vaccines10091432 |
| Alhydrogel® adjuvant 2% | A Novel C-Type Lectin Receptor-Targeted α-Synuclein-Based Parkinson Vaccine I... | 2022 | Vaccines (Basel) | Schmidhuber S. et al. | DOI: 10.3390/vaccines10091432 |
| LPS-EB (LPS from E. coli O111:B4) | Identification of Inflammatory Proteomics Networks of Toll-like Receptor 4 th... | 2022 | Proteomes | Shahinuzzaman A.D.A. et al. | DOI: 10.3390/proteomes10030031 |
| FSL-1 | Toll-like receptor-mediated innate immune responses by recognition of the rec... | 2022 | PLoS One | Saelee C. et al. | DOI: 10.1371/journal.pone.0273517 |
| HEK-Blue™ Detection | Toll-like receptor-mediated innate immune responses by recognition of the rec... | 2022 | PLoS One | Saelee C. et al. | DOI: 10.1371/journal.pone.0273517 |
| Human TLR4 Reporter HEK293 Cells (NF-κB) | Toll-like receptor-mediated innate immune responses by recognition of the rec... | 2022 | PLoS One | Saelee C. et al. | DOI: 10.1371/journal.pone.0273517 |
| HEK-Blue™ Selection | Toll-like receptor-mediated innate immune responses by recognition of the rec... | 2022 | PLoS One | Saelee C. et al. | DOI: 10.1371/journal.pone.0273517 |
| Human TLR2 Reporter HEK293 Cells (NF-κB) | Toll-like receptor-mediated innate immune responses by recognition of the rec... | 2022 | PLoS One | Saelee C. et al. | DOI: 10.1371/journal.pone.0273517 |
| Normocin® - Antimicrobial Reagent | Toll-like receptor-mediated innate immune responses by recognition of the rec... | 2022 | PLoS One | Saelee C. et al. | DOI: 10.1371/journal.pone.0273517 |
| Zeocin® | Gut microbial DL-endopeptidase alleviates Crohn's disease via the NOD2 pathway. | 2022 | Cell Host Microbe | Gao J. et al. | DOI: 10.1016/j.chom.2022.08.002 |
| HEK-Blue™ Detection | Gut microbial DL-endopeptidase alleviates Crohn's disease via the NOD2 pathway. | 2022 | Cell Host Microbe | Gao J. et al. | DOI: 10.1016/j.chom.2022.08.002 |
| Blasticidin | Gut microbial DL-endopeptidase alleviates Crohn's disease via the NOD2 pathway. | 2022 | Cell Host Microbe | Gao J. et al. | DOI: 10.1016/j.chom.2022.08.002 |
| Human NOD2 Reporter HEK293 Cells (NF-κB) | Gut microbial DL-endopeptidase alleviates Crohn's disease via the NOD2 pathway. | 2022 | Cell Host Microbe | Gao J. et al. | DOI: 10.1016/j.chom.2022.08.002 |
| Normocin® - Antimicrobial Reagent | Gut microbial DL-endopeptidase alleviates Crohn's disease via the NOD2 pathway. | 2022 | Cell Host Microbe | Gao J. et al. | DOI: 10.1016/j.chom.2022.08.002 |
| HEK-Blue™ Null2 Cells | Gut microbial DL-endopeptidase alleviates Crohn's disease via the NOD2 pathway. | 2022 | Cell Host Microbe | Gao J. et al. | DOI: 10.1016/j.chom.2022.08.002 |
| Zeocin® | Non-degradable autophagic vacuoles are indispensable for cell competition. | 2022 | Cell Rep. | Akter E. et al. | DOI: 10.1016/j.celrep.2022.111292 |
| Blasticidin | Non-degradable autophagic vacuoles are indispensable for cell competition. | 2022 | Cell Rep. | Akter E. et al. | DOI: 10.1016/j.celrep.2022.111292 |